Bempedoic Acid Gets 'Huge' Win for Primary Prevention in the Statin-Intolerant

(MedPage Today) -- SAN DIEGO -- Bempedoic acid (Nexletol) prevented cardiovascular events in high-risk, statin-intolerant patients who had not yet had an event, a subgroup analysis from the CLEAR Outcomes trial confirmed. In these patients...
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news